Pipeline Momentum GAVIS houses a growing product pipeline with 24 ANDAs filed and pending FDA approval and plans for 8–10 new product launches in the next year, creating multiple near-term opportunities with wholesalers, distributors, chain pharmacies, and GPOs to stock newly approved items.

In-House Fulfillment The 42,000 sq ft Somerset, NJ facility allows in-house warehousing and direct shipping without a third-party logistics provider, enabling tighter inventory control, faster replenishment, and a compelling value proposition for channel partners.

Broad Channel Access GAVIS already sells to virtually all major wholesalers, distributors, chain pharmacies, and GPOs, indicating a broad distribution footprint and potential for rapid take-up of new launches across multiple channels.

Growth Enablement With a small team and revenue in the low range, there is significant upside for sales partnerships, commercial support, and co-marketing to accelerate product uptake and expand market share as new products reach FDA approval.

Strategic Value Historical consideration by Lupin in 2016 highlights the strategic value of GAVIS assets and suggests potential for win-win partnerships, licensing deals, or future acquisition-ready collaboration as products progress in the pipeline.